The Food and Drug Administration's vaccine advisory committee has recommended GlaxoSmithKline’s and Pfizer's respiratory syncytial virus vaccine candidates for older adults, paving the way for approval of the country's first RSV vaccine.

The Vaccines and Related Biological Products Advisory Committee, the same group that reviews COVID-19 vaccines, voted unanimously on Wednesday that vaccine efficiency data for GSK's RSV vaccine for adults 60 years and older were sufficient. The advisory committee voted 7-4 on Tuesday to recommend Pfizer's vaccine candidate for older adults based on its efficacy, with one abstention.

GOP SHIES AWAY FROM SWEEPING HEALTH OVERHAULS IN POST-OBAMACARE REPEAL ERA

"I think an RSV vaccine could have an immense impact on this very common respiratory pathogen. I would love to see more data, which it sounds like we will be available from GSK in April, and then the following year, so I do think ongoing monitoring and data collection and evaluation will be incredibly important," said Henry Bernstein, a member of the advisory committee.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

RSV is a common respiratory illness that typically causes coldlike symptoms, but it can be particularly dangerous for infants and older adults. There is no vaccine approved for the respiratory syncytial virus in the United States.

This is breaking news and will be updated.